This is a plain language summary of a research study called ALPINE. The study involved people who had been diagnosed with, and previously treated at least once for, relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)This Plain Language Summary of Publication article from Future Oncology summarises a research study called ALPINE. The study was designed to directly compare the cancer-fighting effects and side effects of  zanubrutinib and ibrutinib as treatment for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Visit the Future Medicine using the link to read the article.

The original article on which this summary is based is called ‘Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia’ and was published in The New England Journal of Medicine. 

Visit The New England Journal of Medicine using the link to read the article.